| Literature DB >> 31950363 |
Jinti Lin1,2, Jun Wu3, Shuaibo Sun1,2, Kai Chen1,2, Hongqiang Wu1,2, Renjin Lin1,2, Chengwei Zhou1,2, Jianzhong Kong1,2, Kailiang Zhou4,5, Xiaolong Shui6,7.
Abstract
Osteoporotic bones heal more slowly and ineffectively than normal bones. A combination of antibodies against sclerosing protein (Scl-Ab), and parathyroid hormone 1-34 (PTH 1-34) may improve healing. A standard osteoporotic rat model was established 12 weeks after bilateral ovarian resection (OVX). Bone defects were created in the right femora of 80 rats, which were randomly divided into 4 groups: control, Scl-Ab (25 mg/kg twice weekly), PTH (60 μg/kg of PTH 1-34 three times a week) and PTH plus Scl-Ab. After 12 weeks of treatment the rats were sacrificed and blood and the distal femora were harvested for biochemical evaluation, histology, microcomputed tomography and biomechanical testing. Compared to the control group, monotherapy and combination therapy with PTH and/or Scl-Ab promoted the formation of new bone, enhanced maximum femoral loading and increased the levels of procollagen type I N‑terminal propeptide (PINP) and osteocalcin. The administration of PTH + Scl-Ab maximally enhanced bone defect healing. Combination treatment was better than either treatment alone, indicating a synergistic effect.Entities:
Keywords: Antisclerostin antibody; Bone defect; Experimental animal model; Osteoporosis; Parathyroid hormone
Mesh:
Substances:
Year: 2020 PMID: 31950363 DOI: 10.1007/s00391-019-01685-2
Source DB: PubMed Journal: Z Gerontol Geriatr ISSN: 0948-6704 Impact factor: 1.281